Almac-Queen's Cancer Expert to Lead £4.4m Collaboration
An investment of £4.4m ($7m) in a unique academic-business collaboration between Almac and Queen’s University, Belfast (QUB) will help develop better tests for diagnosing and treating prostate, ovarian, and breast cancer.
The research initiative, based at the Center for Cancer Research and Cell Biology at Queen’s, will be led by Professor Richard Kennedy, one of Almac’s experts in personalized medicine—which tailors specific treatment to each cancer patient.
Invest Northern Ireland and The McClay Foundation, the charitable trust established by the late Sir Allen McClay, are partnering to fund the lab facilities and staff costs. Invest NI has offered the Almac Group and QUB £1.5 million ($2.39 million) of support towards the collaboration, which includes part funding from the European Regional Development Fund.
Professor Kennedy, the newly appointed McClay Chair of Experimental Cancer Medicine at Queen’s University—a joint appointment with Almac—said the project was an excellent example of how business and academia could work together in the fight against cancer, the leading cause of death in Western civilizations.
He explained: “The research will involve using technology developed by Almac which will allow us to analyze large numbers of patient tumours collected by Queen’s. We will develop these tests to help clinicians to better understand prostate, ovarian, and breast cancer and prescribe the appropriate treatments tailored to the specific patient. We hope this will then improve the chances of cure using chemotherapy and radiotherapy."
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
